2019, Number 4
Synchronous cancer, gastric adenocarcinoma and renal cell cancer
Full text
Language: English/Spanish [Versión en español]
References: 18
Page: 294-299
PDF size: 324.27 Kb.
ABSTRACT
We present the case of 68-year-old male, with abdominal distension, dyspepsia, progressive dysphagia from solids to liquids. A study protocol was started with contrast tomography with thickening of the antral and pyloric mucosa of 1.7 cm in addition to right renal tumor. High endoscopy is performed, which reports infiltrating gastric neoplasm (Borrmann II adenocarcinoma). Surgical intervention that was carried out: total gastrectomy, D1 lymphadenectomy, esophageal aneurysm with circular stapler and Roux-en-Y stapler with intravenous lateral-terminal anastomosis in addition to right radical nephrectomy. The diagnosis was made of gastric adenocarcinoma PT4AN1M0 EC IIIA and renal cell carcinoma variety chromophobe PT2N0M0 ECII. Synchronous cancer presentations in cancer patients are infrequent. The incidence of synchronous renal cell carcinoma with gastric cancer is quite low (0.11-0.37%). In our country, renal cancer accounts for 1.5% of all neoplasms. We present the case of a synchronous gastric cancer with a renal tumor of rare histological origin.INTRODUCTION
Synchronous neoplasias are infrequent. In our country, renal cancer represents 1.5% of all neoplasms1 and usually manifests in advanced stages with the characteristic triad of hematuria, pain, and abdominal tumor.1 Four histological types are currently recognized: clear cell carcinoma, chromophobe cell carcinoma, papillary or chromophilic carcinoma, and carcinoma of the distal collecting ducts. Chromophobe cell carcinoma (CCC) is a renal epithelial neoplasm of the adult presenting between the fourth and sixth decades of life. It is little known in our environment, hence frequently diagnosed as clear cell carcinoma.2 Gastric cancer (GC) is the most frequent gastrointestinal neoplasm worldwide. It occupies the second place in cancer mortality worldwide and represented 3% of the cancers diagnosed in Mexico in the year 2000. Sánchez-Barriga reports that, between 2002-2012, 69,107 patients died from GC in Mexico. In 2000, there were 5,003 deaths from GC and 5,459 patients died from it in 2012. The age-adjusted mortality rate for GC was 5.6 per 100,000 population in 2012, and this study shows that the GC mortality rate in Mexico decreased from 7.5 per 100,000 population in the year 2000.3-6
From 2005 to 2015 (10 years), a total of 21,761 deaths from gastric cancer were registered, with an average mortality rate of 8.1 × 100,000 in Social Security affiliates. The overall mortality rate of gastric cancer has shown a gradual decrease (2005 rate 8.08 × 100,000 versus 2015: rate .6.9 × 100,000 p < 0.001).4
The incidence of stomach cancer is highest in East Asia, where diagnosis in early stages (stage IA) is 30%. 70% is identified in advanced stages, due to screening programs, and 88% present at stage III or IV at diagnosis.5
We present a case of concomitant gastrectomy and nephrectomy in a patient with synchronous gastric and renal cell cancers. The presence of these neoplasms in synchrony has a low incidence and there have been few case reports and review of the literature. It is a challenge for the general surgeon and the oncologist to perform such a complex surgical procedure.
PRESENTATION OF THE CASE
A 68 year-old male patient with history of diabetes mellitus, smoking, and chronic alcoholism for more than 20 years. He denied surgical history. The patient presented with intermittent abdominal distension, dyspepsia, progressive dysphagia from solids to liquids. He denied weight loss or data of gastrointestinal tract bleeding. A CT scan with intravenous contrast reported a right renal tumor of 7 × 6 × 4 cm with rounded edges, well defined, and a heterogeneous hypodense center related to cystic or necrotic degeneration (Figure 1). After intravenous contrast, a "claw sign" was present, with enhancement at 20 HU and a delayed triphasic phase enhancement of 10 HU. Also, a distended stomach with thickening of the antral and pyloric mucosa of 1.7 cm was found, with no hepatic or distant metastases. Panendoscopy showed infiltrating gastric neoplasia (Borrmann II adenocarcinoma) (Figure 2). The histopathological result of the gastric biopsy reported a poorly differentiated diffuse infiltrating adenocarcinoma with signet ring cells. The CA 19-9 marker value was 126 U/ml.
A tumor was found in the lesser curvature of the stomach, the antrum, and pylorus, with extension towards the celiac trunk, including the left gastric artery and the hepatic artery up to the gastroduodenal artery. It also extended to the posterior aspect, with adherences to the body of the pancreas, tumor implants in the transverse mesocolon near the angle of Treitz, and adenomegaly in the greater omentum. The esophagogastric junction was free of tumor. It was stratified as T4aN2M0.
Total gastrectomy, D1 lymphadenectomy, esophago-jejunal anastomosis with 29 mm circular stapler, and entero-enteric latero-terminal anastomosis with 55 mm linear Y-de-Roux stapler (Figures 3 and 4).
The right renal region was explored and scarce citrine free fluid was found, with a solid tumor in the upper pole of the right kidney, measuring 10 × 5 cm, and a renal vein without thrombus. The renal tumor was assigned a staging of T2bN0M0. During the same surgical procedure, a radical right nephrectomy was done.
The patient had a good postoperative evolution, with no data of anastomosis leakage. He tolerated the oral route, ambulated on the fifth postoperative day, and was discharged on the seventh day.
The definitive histopathological study reported:
- A) Esophageal mucosa, negative for neoplastic cells.
- B) A 10 cm tumor. Microscopically, a poorly differentiated diffuse infiltrating adenocarcinoma with signet ring cells. It infiltrated to the serosa, with extensive lymphatic and perineural invasion. There were implants in the omentum and metastasis to two lymph nodes. The proximal and distal surgical edges were tumor-free.
- C) Renal cell carcinoma, chromophobe variety, 7.5 cm of greater diameter, without infiltration to the capsule, negative hilum structures for neoplasia.
Gastric adenocarcinoma PT4AN1M0 EC IIIA and renal cell carcinoma chromophobe variety PT2N0M0 ECII were diagnosed.
DISCUSSION
The incidence of gastric cancer in presentation with another synchronous primary cancer varies from 2 to 10%. Colorectal, lung, and liver tumors are often reported in the literature; however, synchronous renal cell carcinoma is rare (0.11-0.37%). The incidence of synchronous cancer is higher in early-stage gastric neoplasms than in advanced stages (5.2% versus 2.4%).7 In this work, the definition of Warren and Gates8 was used to identify synchronous tumors: each tumor must present as a definite picture of malignancy, each must be distinct, and the possibility that one is a metastasis must be excluded.
Ikeda et al9 state that gastric cancer has been increasingly diagnosed in early stages in Japan, with an increase in synchronous primary neoplasms, specifically colorectal and pulmonary. Eighty percent of lung tumors were diagnosed as metachronous. 65 to 80% of colorectal, renal, and gallbladder tumors were synchronous. Concerning age at presentation and gender, primary tumors of the stomach occurred more frequently in men and increased directly proportional to age. In this study, the second primary tumor was the leading cause of death.
Another tumor that occurs synchronously with other gastrointestinal neoplasms is the gastrointestinal stromal tumor (GIST). The malignant neoplasm most frequently associated with GIST is gastric cancer, followed by esophageal cancer. Multiple studies show that 14-27% of patients with GIST have synchronous gastrointestinal neoplasms.10
Renal cell carcinoma (RCC) generally has a higher incidence between 60 and 70 years of age, with a predominance in males. Its most relevant risk factors are smoking and obesity. Mortality from RCC has decreased steadily over the last decades. A recent analysis showed a decrease in mortality in men, from 4.8 per 100,000 from 1990 to 1994, to 4.1 per 100,000 from 2000 to 2004. This decrease in mortality is also attributed to incidental diagnosis by radiodiagnostic imaging.6,11
Chromophobe cell carcinoma is an uncommon malignant tumor, accounting for 5-8% of RCCs, and is thought to arise from the intercalated cells of the collecting ducts. These tumors present in a sporadic or familial pattern, and clinically in 10-20% of cases, and tumors larger than 10 cm present with the classic clinical triad of vertebral rib pain, palpable tumor, and hematuria. Pulmonary metastases are the most common (50%) and bone metastases (33%), and radical nephrectomy is the treatment of choice.7,12
In gastric cancer, resectability is 60-80% and postoperative mortality ranges from 6 to 14%. The five-year survival rate is 8-26%.13
In terms of histological type, gastric carcinomas are classified as follows: signet ring carcinoma (SRC) and non-signet ring carcinoma (NSC), the latter group includes tubular, papillary, mucinous, and other less frequent varieties such as adenosquamous and pure squamous. Gastric cancer originates in the mucosa without metaplasia at the proliferative zone of the neck of the glands and, according to the classification of the World Health Organization (WHO). More than 50% of the neoplastic cells are signet ring cells. This histological variety represents between 3% and 39% of gastric carcinomas.14,15
The etiology and pathogenesis of multiple primary neoplasms are still not clearly explained. The interaction of genetic and environmental risk factors common to both cancers could cause multiple malignancies such as renal cell cancer and gastric adenocarcinoma. Common risk factors include smoking, pollution, ultraviolet light, chemotherapy, radiotherapy, and endocrine factors. These factors may act individually or in combination.16
CONCLUSION
Concomitant surgery to treat gastric cancer and renal cell carcinoma is rare. Patients with gastric cancer are at risk of developing an additional second primary form of cancer, so surgeons should attempt to diagnose synchronous cancers. The risk factor mostly reported in the world literature is smoking, which influences gastric cancer and the development of synchronous neoplasms, either pulmonary or renal. Most renal tumors are found incidentally by radiodiagnostic studies such as tomography.17
The survival rate for gastric adenocarcinoma is 84.1% at three years and 69.3% at five years in patients with a second primary cancer. At ten years, survival rates are 69.3% for patients with gastric cancer with no other primary and 40.1% with a second primary cancer. This difference between the two groups is statistically significant.11,18
Current American Urological Association guidelines regarding the treatment of clinical stage I renal masses lack an explicit recommendation for clinicians to be aware of the possibility of a second primary neoplasm.8
REFERENCES
AFFILIATIONS
1 Resident in General Surgery.
2 Professor of General Surgery.
Considerations and ethical responsibility: Data privacy. In accordance with the protocols established at the authors\' work center, the authors declare that they have followed the protocols on patient data privacy and preserved their anonymity.
The informed consent of the patient referred to in the article is in the possession of the author.
Funding: No financial support was received for this study.
Conflict of interest: The authors declare that there is no conflict of interest in this study.
CORRESPONDENCE
Edwin Leopoldo Maldonado García. E-mail: edwinlmg@gmail.comReceived: 13/10/2017. Accepted: 13/05/2019